Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GRETEL TRULLENQUE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1720076144
CMS profile
32746
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,983.09

17 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,172.19 6
Food and Beverage $810.90 11

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $1,783.82 16
Galderma Laboratories, L.P. $199.27 1

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GRETEL TRULLENQUE

NPI 1720076144 · CMS profile ID 32746

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720076144?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720076144?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720076144?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1720076144?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

17 matching records · $1,983.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 17 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–17 of 17.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Galderma Laboratories, L.P. $199.2711/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145332989 CMS
E.R. Squibb & Sons, L.L.C. $70.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786936 CMS
E.R. Squibb & Sons, L.L.C. $75.0010/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786939 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786943 CMS
E.R. Squibb & Sons, L.L.C. $75.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786946 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786950 CMS
E.R. Squibb & Sons, L.L.C. $70.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786953 CMS
E.R. Squibb & Sons, L.L.C. $140.7110/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786957 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786961 CMS
E.R. Squibb & Sons, L.L.C. $75.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786964 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786968 CMS
E.R. Squibb & Sons, L.L.C. $70.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786972 CMS
E.R. Squibb & Sons, L.L.C. $155.8610/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786975 CMS
E.R. Squibb & Sons, L.L.C. $448.7910/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786979 CMS
E.R. Squibb & Sons, L.L.C. $225.9410/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786983 CMS
E.R. Squibb & Sons, L.L.C. $225.9410/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786987 CMS
E.R. Squibb & Sons, L.L.C. $40.6610/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101786990 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,374.49 69
PY2020 $1,355.75 79
PY2021 $259.48 14
PY2022 $192.27 9
PY2023 $2,004.82 9
PY2024 $1,983.09 17
PY2025 $1,220.64 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,629,687.56 10
PY2024 Principal investigator $1,001,480.43 22
PY2023 Principal investigator $393,727.30 31
PY2022 Principal investigator $743,619.78 33
PY2021 Principal investigator $102,847.74 117
PY2020 Principal investigator $1,098,095.92 216
PY2019 Principal investigator $335,867.48 106

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,354.00 12/26/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256373
Principal investigator 1 ABBVIE INC. $653.90 12/15/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889825383
Principal investigator 1 Janssen Research & Development, LLC $1,401.00 12/01/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256371
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 11/17/2022 Non-covered Recipient Entity
Floridian Research Institute, Llc
A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus No dispute reported 06/30/2026 935611679
Principal investigator 1 Janssen Research & Development, LLC $3,949.00 10/31/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256363
Principal investigator 1 Janssen Research & Development, LLC $10,902.00 10/31/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256367
Principal investigator 1 SANOFI US SERVICES INC. $5,426.68 10/27/2022 Non-covered Recipient Entity
Floridian Research Institute, Llc
A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus No dispute reported 06/30/2026 935611667
Principal investigator 1 Eli Lilly and Company $1,351.00 10/20/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917826527
Principal investigator 1 ABBVIE INC. $2,038.20 10/12/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889814697
Principal investigator 1 Janssen Research & Development, LLC $60,710.00 10/03/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256365
Principal investigator 1 Janssen Research & Development, LLC $81,451.00 10/03/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256369
Principal investigator 1 ABBVIE INC. $9,232.40 09/08/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889809571
Principal investigator 1 Janssen Research & Development, LLC $203,178.00 08/29/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256359
Principal investigator 1 Janssen Research & Development, LLC $110,168.00 08/09/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256361
Principal investigator 1 ABBVIE INC. $65.00 07/07/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889799035
Principal investigator 1 Janssen Research & Development, LLC $1,632.00 06/27/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256351
Principal investigator 1 Janssen Research & Development, LLC $816.00 06/27/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256353
Principal investigator 1 Janssen Research & Development, LLC $20,455.00 06/27/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256355
Principal investigator 1 Janssen Research & Development, LLC $36,590.00 06/27/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256357
Principal investigator 1 ABBVIE INC. $1,153.30 06/08/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889794387
Principal investigator 1 Janssen Research & Development, LLC $2,708.00 05/30/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256345
Principal investigator 1 Janssen Research & Development, LLC $48,622.00 05/27/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256349
Principal investigator 1 Janssen Research & Development, LLC $25,035.00 05/09/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256347
Principal investigator 1 ABBVIE INC. $683.40 05/05/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889789875
Principal investigator 1 ABBVIE INC. $984.90 04/07/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889783887
Principal investigator 1 Incyte Corporation $2,718.00 03/25/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243041
Principal investigator 1 ABBVIE INC. $1,178.80 03/08/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779429
Principal investigator 1 Janssen Research & Development, LLC $15,580.00 03/07/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256337
Principal investigator 1 Janssen Research & Development, LLC $35,670.00 03/07/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256343
Principal investigator 1 Janssen Research & Development, LLC $12,179.00 02/04/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256339
Principal investigator 1 Janssen Research & Development, LLC $39,077.00 02/04/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 885256341
Principal investigator 1 ABBVIE INC. $2,835.10 02/03/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889775391
Principal investigator 1 ABBVIE INC. $822.10 01/06/2022 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889772779